Alberto Chiappori, MD, discusses the inclusion of patients with CNS metastases in the eXALT3 trial of ensartinib in ALK-positive NSCLC.
Alberto Chiappori MD
Advertisement
Alberto Chiappori, MD, is a senior member of Oncology and Medicine for the Thoracic Oncology Program at the H. Lee Moffitt Cancer Center and Research Institute.
Articles by Alberto Chiappori MD
Alberto Chiappori, MD, discusses the selection between frontline treatment options, including ensartinib, in ALK-positive non–small cell lung cancer.
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas
ByShailaja Raj MD,Gregory Springett MD PhD,Daniel Indelicato MD,Marilyn Bui, MD, PhD,Anthony Conley MD,Sergio Lavilla-Alonso PhD,Xiuhua Zhao MS,Dungsa Chen PhD,Randy Haysek MD,Ricardo Gonzalez MD,Douglas Letson MD,Steven Eric Finkelstein MD PhD,Alberto Chiappori MD,Dimitry Gabrilovitch MD PhD,Scott J. Antonia, MD, PhD
Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Advertisement
Latest Updated Articles
Dr Chiappori on the Integration of Ensartinib Into the NSCLC Treatment ArsenalPublished: March 11th 2025 | Updated:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasPublished: February 22nd 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
5